Q-omics provides the consensus-scored ZNF192P2 profile across patient tissues and cancer cell-line models. ZNF192P2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ZNF192P2 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, ZNF192P2 RNA expression shows 8,986 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, BLCA, and THYM as cancer lineages where ZNF192P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF192P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF192P2 survival associations across molecular data types. ZNF192P2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF192P2 RNA expression–survival associations across cancer types. High ZNF192P2 expression shows unfavorable associations in DLBC, THCA, LIHC, CESC and READ, but favorable associations in UCS. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for ZNF192P2 RNA expression.
This table summarizes ZNF192P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF192P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF192P2 shows lower tumor expression in BLCA and higher tumor expression in HNSC, PRAD and KIRC. The BLCA box plot shows higher ZNF192P2 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p = .029).
This table shows molecular features associated with ZNF192P2 in patient tissues and cancer cell lines. In patient samples, ZNF192P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
